Non-viral Vectors for RNA Delivery

Overview

Journal J Control Release

Specialty Pharmacology

Date 2022 Jan 12

PMID 35016918

Authors

Yi Yan

Xiao-Yu Liu

An Lu

Xiang-Yu Wang

Lin-Xia Jiang

Jian-Cheng Wang

Affiliations

Soon will be listed here.

Abstract

RNA-based therapy is a promising and potential strategy for disease treatment by introducing exogenous nucleic acids such as messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides (ASO) to modulate gene expression in specific cells. It is exciting that mRNA encoding the spike protein of COVID-19 (coronavirus disease 2019) delivered by lipid nanoparticles (LNPs) exhibits the efficient protection of lungs infection against the virus. In this review, we introduce the biological barriers to RNA delivery in vivo and discuss recent advances in non-viral delivery systems, such as lipid-based nanoparticles, polymeric nanoparticles, N-acetylgalactosamine (GalNAc)-siRNA conjugate, and biomimetic nanovectors, which can protect RNAs against degradation by ribonucleases, accumulate in specific tissue, facilitate cell internalization, and allow for the controlled release of the encapsulated therapeutics.

Citing Articles

Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer.

Cai J, Liu Z, Chen S, Zhang J, Li H, Wang X Exp Hematol Oncol. 2025; 14(1):35.

PMID: 40075480 PMC: 11905684. DOI: 10.1186/s40164-025-00625-8.

Unleashing the potential of mRNA: Overcoming delivery challenges with nanoparticles.

Chen Q, Huo K, Ji S, Pang S, Sun T, Niu Y Bioeng Transl Med. 2025; 10(2):e10713.

PMID: 40060761 PMC: 11883111. DOI: 10.1002/btm2.10713.

piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer.

Qin H, Han Y, Li J, Wu Q, Du Y, Li Q NPJ Precis Oncol. 2025; 9(1):65.

PMID: 40057617 PMC: 11890584. DOI: 10.1038/s41698-025-00840-w.

Advances and prospects of RNA delivery nanoplatforms for cancer therapy.

Attia M, Kijanka G, Nguyen N, Zhang J, An H Acta Pharm Sin B. 2025; 15(1):52-96.

PMID: 40041887 PMC: 11873661. DOI: 10.1016/j.apsb.2024.09.009.

Advanced Nanomedicine Delivery Systems for Cardiovascular Diseases: Viral and Non-Viral Strategies in Targeted Therapy.

Chen Q, Yu T, Gong J, Shan H Molecules. 2025; 30(4).

PMID: 40005272 PMC: 11858567. DOI: 10.3390/molecules30040962.

References

Patil Y, Swaminathan S, Sadhukha T, Ma L, Panyam J . The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2009; 31(2):358-65. PMC: 2783414. DOI: 10.1016/j.biomaterials.2009.09.048. View

Wei W, Sun J, Guo X, Chen X, Wang R, Qiu C . Microfluidic-Based Holonomic Constraints of siRNA in the Kernel of Lipid/Polymer Hybrid Nanoassemblies for Improving Stable and Safe In Vivo Delivery. ACS Appl Mater Interfaces. 2020; 12(13):14839-14854. DOI: 10.1021/acsami.9b22781. View

Tao S, Rui B, Wang Q, Zhou D, Zhang Y, Guo S . Extracellular vesicle-mimetic nanovesicles transport LncRNA-H19 as competing endogenous RNA for the treatment of diabetic wounds. Drug Deliv. 2018; 25(1):241-255. PMC: 6058500. DOI: 10.1080/10717544.2018.1425774. View

Wang X, Liang Q, Mao Y, Zhang R, Deng Q, Chen Y . Bioreducible, branched poly(β-amino ester)s mediate anti-inflammatory ICAM-1 siRNA delivery against myocardial ischemia reperfusion (IR) injury. Biomater Sci. 2020; 8(14):3856-3870. DOI: 10.1039/d0bm00631a. View

Ding F, Mou Q, Ma Y, Pan G, Guo Y, Tong G . A Crosslinked Nucleic Acid Nanogel for Effective siRNA Delivery and Antitumor Therapy. Angew Chem Int Ed Engl. 2018; 57(12):3064-3068. DOI: 10.1002/anie.201711242. View

Park H, Jeon E, Lee J, Hong S, Cho A, Lee J . Galactosylated Lipidoid Nanoparticles for Delivery of Small Interfering RNA to Inhibit Hepatitis C Viral Replication In Vivo. Adv Healthc Mater. 2016; 5(22):2931-2941. DOI: 10.1002/adhm.201600416. View

Ernsting M, Murakami M, Roy A, Li S . Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013; 172(3):782-94. PMC: 3891171. DOI: 10.1016/j.jconrel.2013.09.013. View

Tosar J, Witwer K, Cayota A . Revisiting Extracellular RNA Release, Processing, and Function. Trends Biochem Sci. 2021; 46(6):438-445. PMC: 8122015. DOI: 10.1016/j.tibs.2020.12.008. View

Lokugamage M, Sago C, Gan Z, Krupczak B, Dahlman J . Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands. Adv Mater. 2019; 31(41):e1902251. PMC: 6819129. DOI: 10.1002/adma.201902251. View

10.

Veiga N, Diesendruck Y, Peer D . Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. Adv Drug Deliv Rev. 2020; 159:364-376. DOI: 10.1016/j.addr.2020.04.002. View

11.

Nie D, Dai Z, Li J, Yang Y, Xi Z, Wang J . Cancer-Cell-Membrane-Coated Nanoparticles with a Yolk-Shell Structure Augment Cancer Chemotherapy. Nano Lett. 2019; 20(2):936-946. DOI: 10.1021/acs.nanolett.9b03817. View

12.

Zhou J, Wu J, Hafdi N, Behr J, Erbacher P, Peng L . PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb). 2006; (22):2362-4. DOI: 10.1039/b601381c. View

13.

Xue H, Ding F, Zhang J, Guo Y, Gao X, Feng J . DNA tetrahedron-based nanogels for siRNA delivery and gene silencing. Chem Commun (Camb). 2019; 55(29):4222-4225. DOI: 10.1039/c9cc00175a. View

14.

Schulz-Siegmund M, Aigner A . Nucleic acid delivery with extracellular vesicles. Adv Drug Deliv Rev. 2021; 173:89-111. DOI: 10.1016/j.addr.2021.03.005. View

15.

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

16.

Mui B, Tam Y, Jayaraman M, Ansell S, Du X, Tam Y . Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids. 2013; 2:e139. PMC: 3894582. DOI: 10.1038/mtna.2013.66. View

17.

Fernandes M, Lopes I, Teixeira J, Botelho C, Gomes A . Exosome-like Nanoparticles: A New Type of Nanocarrier. Curr Med Chem. 2019; 27(23):3888-3905. DOI: 10.2174/0929867326666190129142604. View

18.

Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q . Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2020; 268:120546. DOI: 10.1016/j.biomaterials.2020.120546. View

19.

Somiya M, Kuroda S . Development of a virus-mimicking nanocarrier for drug delivery systems: The bio-nanocapsule. Adv Drug Deliv Rev. 2015; 95:77-89. DOI: 10.1016/j.addr.2015.10.003. View

20.

Uchida S, Kinoh H, Ishii T, Matsui A, Tockary T, Takeda K . Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials. 2016; 82:221-8. DOI: 10.1016/j.biomaterials.2015.12.031. View